Device Trial Radar · NCT04267575
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Last checked: Nov 19, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Actual
Start
Jul 30, 2019
Primary completion
Apr 14, 2021
Study completion Apr 14, 2023
Sponsor
- Lead sponsor
- Jerome Canady, M.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.
Conditions
- Recurrent Malignant Solid Neoplasm
- Stage IV Breast Cancer
- Stage IV Prostate Cancer
- Stage IV Pancreatic Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Colon Cancer
- Stage IV Colorectal Cancer
- Stage IV Liver Cancer
- Stage IV Renal Cell Cancer
- Stage IV Rectal Cancer
- Stage IV Lung Cancer
- Stage IV Small Intestinal Cancer
- Stage IV Gastric Cancer
- Stage IV Bladder Cancer
Interventions
Canady Helios Cold Plasma ScalpelDevice
Device used to distribute cold plasma energy at the resected tumor margins.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Complications Due To Cold Plasma ApplicationTime frame: Immediate after application of cold plasma, followed by 3 months, 6 months, 12 months and 15 month observations.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Canady Surgical Group PC
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.